Catalyst Pharmaceuticals, Inc. (CPRX)
NASDAQ: CPRX · Real-Time Price · USD
23.37
+0.61 (2.68%)
At close: May 9, 2025, 4:00 PM
22.99
-0.38 (-1.63%)
After-hours: May 9, 2025, 7:13 PM EDT
Catalyst Pharmaceuticals Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for Catalyst Pharmaceuticals stock have an average target of 32.29, with a low estimate of 29 and a high estimate of 36. The average target predicts an increase of 38.17% from the current stock price of 23.37.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 3, 2025.
Analyst Ratings
The average analyst rating for Catalyst Pharmaceuticals stock from 7 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 3 | 3 | 4 | 4 | 4 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 8 | 8 | 8 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Baird | Baird | Buy Maintains $28 → $32 | Buy | Maintains | $28 → $32 | +36.93% | Mar 3, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $35 | Strong Buy | Reiterates | $35 | +49.76% | Feb 28, 2025 |
| Stephens & Co. | Stephens & Co. | Buy Reiterates $33 | Buy | Reiterates | $33 | +41.21% | Feb 27, 2025 |
| Baird | Baird | Buy Initiates $28 | Buy | Initiates | $28 | +19.81% | Feb 4, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $30 → $35 | Strong Buy | Maintains | $30 → $35 | +49.76% | Jan 10, 2025 |
Financial Forecast
Revenue This Year
568.38M
from 491.73M
Increased by 15.59%
Revenue Next Year
618.95M
from 568.38M
Increased by 8.90%
EPS This Year
1.45
from 1.31
Increased by 10.95%
EPS Next Year
1.71
from 1.45
Increased by 17.66%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 593.9M | 696.7M | 830.3M | ||
| Avg | 568.4M | 619.0M | 694.7M | ||
| Low | 539.7M | 547.0M | 588.1M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 20.8% | 22.6% | 34.2% | ||
| Avg | 15.6% | 8.9% | 12.2% | ||
| Low | 9.8% | -3.8% | -5.0% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 1.85 | 2.38 | 2.48 | ||
| Avg | 1.45 | 1.71 | 1.90 | ||
| Low | 1.23 | 1.09 | 1.40 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 41.1% | 64.0% | 44.9% | ||
| Avg | 11.0% | 17.7% | 11.1% | ||
| Low | -6.5% | -25.2% | -18.1% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.